PE20180250A1 - ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT - Google Patents

ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT

Info

Publication number
PE20180250A1
PE20180250A1 PE2017002473A PE2017002473A PE20180250A1 PE 20180250 A1 PE20180250 A1 PE 20180250A1 PE 2017002473 A PE2017002473 A PE 2017002473A PE 2017002473 A PE2017002473 A PE 2017002473A PE 20180250 A1 PE20180250 A1 PE 20180250A1
Authority
PE
Peru
Prior art keywords
thiazole
trifluoromethyl
rorgamma
hydroxypropan
hexafluoro
Prior art date
Application number
PE2017002473A
Other languages
English (en)
Spanish (es)
Inventor
Hariharan Venkatesan
Virginia Tanis
Steven Goldberg
Anne M Fourie
Xiaohua Xue
Olaf Kinzel
Christian Gege
Christoph Steeneck
Gerald Kleymann
Thomas Hoffmann
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20180250A1 publication Critical patent/PE20180250A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2017002473A 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT PE20180250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
PE20180250A1 true PE20180250A1 (es) 2018-02-02

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002473A PE20180250A1 (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT
PE2017000795A PE20171649A1 (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE ROR(gamma)T

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017000795A PE20171649A1 (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE ROR(gamma)T

Country Status (40)

Country Link
US (2) US9850236B2 (enExample)
EP (2) EP3354651B1 (enExample)
JP (3) JP6998204B2 (enExample)
KR (2) KR20170127580A (enExample)
CN (3) CN107827841A (enExample)
AR (2) AR102480A1 (enExample)
AU (2) AU2015339087B2 (enExample)
BR (2) BR112017008816A2 (enExample)
CA (1) CA2965512C (enExample)
CL (3) CL2017001042A1 (enExample)
CO (1) CO2017005014A2 (enExample)
CR (2) CR20170166A (enExample)
CY (1) CY1121716T1 (enExample)
DK (1) DK3212643T3 (enExample)
EA (2) EA033699B1 (enExample)
EC (1) ECSP17033054A (enExample)
ES (2) ES2858503T3 (enExample)
GT (1) GT201700090A (enExample)
HR (1) HRP20190900T1 (enExample)
HU (1) HUE043624T2 (enExample)
IL (2) IL251865A0 (enExample)
JO (2) JOP20200117A1 (enExample)
LT (1) LT3212643T (enExample)
MA (1) MA40873B1 (enExample)
ME (1) ME03426B (enExample)
MX (2) MX369567B (enExample)
PE (2) PE20180250A1 (enExample)
PH (2) PH12017500800A1 (enExample)
PL (1) PL3212643T3 (enExample)
PT (1) PT3212643T (enExample)
RS (1) RS58613B1 (enExample)
SG (2) SG10201805355YA (enExample)
SI (1) SI3212643T1 (enExample)
SM (1) SMT201900290T1 (enExample)
SV (1) SV2017005429A (enExample)
TR (1) TR201907763T4 (enExample)
TW (2) TWI705057B (enExample)
UY (2) UY36377A (enExample)
WO (1) WO2016069974A1 (enExample)
ZA (3) ZA201703679B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
CN112118841A (zh) 2018-03-12 2020-12-22 爱思凯利尔生物科学私人有限责任公司 螺环ROR-γ调节剂
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
JP2021527660A (ja) * 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN119528866B (zh) * 2024-11-28 2025-10-17 河南农业大学 一种含双三氟甲基的香豆素叔醇类化合物及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
NZ529043A (en) 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7138403B2 (en) 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
SA04250288B1 (ar) * 2003-09-19 2008-07-19 سولفاي فارماسوتيكالز بي . في مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid
WO2006124687A1 (en) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2591674B1 (de) 2008-07-17 2016-01-13 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
US8377962B2 (en) * 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
PT3002008T (pt) 2010-03-11 2018-12-24 Univ New York Compostos de amido como moduladores roryt e suas utilizações
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
EP2660597B1 (en) 2010-12-28 2017-09-13 ARKRAY, Inc. Method for determining condition of oral cavity and analytical tool, apparatus and program used for the method
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
EP2753327A4 (en) 2011-09-09 2015-04-08 Univ New York AMIDOVER BINDINGS AS RORYT MODULATORS AND ITS USE
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
BR112014029868A2 (pt) * 2012-05-31 2017-06-27 Phenex Pharmaceuticals Ag compostos, e, composição farmacêutica
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
PE20151203A1 (es) * 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
US9624210B2 (en) * 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
CN105308037B (zh) 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
EP3046906B1 (en) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
US9346782B2 (en) * 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
KR20160068948A (ko) * 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyt의 이차 알코올 퀴놀리닐 조절제
RS58650B1 (sr) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gama (rory) modulatori
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
CN106061947B (zh) 2014-01-06 2019-12-03 百时美施贵宝公司 环己基砜RORγ调节剂
EP3092221B1 (en) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Heterocyclic sulfones as ror-gamma modulators
ES2669208T3 (es) 2014-01-06 2018-05-24 Bristol-Myers Squibb Company Derivados de pirrolidinilsulfona y su uso como moduladores de ROR gamma
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
US9845319B2 (en) 2014-10-30 2017-12-19 Janssen Pharmaceutiuca NV Amide substituted thiazoles as modulators of RORyt
CN107108598B (zh) 2014-10-30 2020-11-17 詹森药业有限公司 作为Rorγt调节剂的噻唑

Also Published As

Publication number Publication date
JP6623270B2 (ja) 2019-12-18
ZA201805861B (en) 2019-11-27
JP6998204B2 (ja) 2022-02-04
ES2858503T3 (es) 2021-09-30
TWI667230B (zh) 2019-08-01
AU2019200228A1 (en) 2019-01-31
RS58613B1 (sr) 2019-05-31
EP3354651A1 (en) 2018-08-01
HUE043624T2 (hu) 2019-08-28
CY1121716T1 (el) 2020-07-31
ES2724556T3 (es) 2019-09-12
CN107827841A (zh) 2018-03-23
EA033699B1 (ru) 2019-11-18
CO2017005014A2 (es) 2017-08-31
MA40873B1 (fr) 2019-07-31
PL3212643T3 (pl) 2019-08-30
PT3212643T (pt) 2019-06-17
CL2017001042A1 (es) 2017-12-01
PH12017502105A1 (en) 2019-11-25
ZA201703679B (en) 2019-06-26
SV2017005429A (es) 2017-10-17
SI3212643T1 (sl) 2019-04-30
EP3212643A1 (en) 2017-09-06
CA2965512A1 (en) 2016-05-06
UY37517A (es) 2018-01-31
IL255648A (en) 2018-01-31
US20160122336A1 (en) 2016-05-05
UY36377A (es) 2016-04-29
TW201927759A (zh) 2019-07-16
AU2015339087B2 (en) 2020-01-23
ECSP17033054A (es) 2018-01-31
JP2020180129A (ja) 2020-11-05
EA201891562A3 (ru) 2019-04-30
HRP20190900T1 (hr) 2019-07-12
US9850236B2 (en) 2017-12-26
AU2019200228B2 (en) 2020-04-16
SMT201900290T1 (it) 2019-07-11
GT201700090A (es) 2019-08-08
TW201629027A (zh) 2016-08-16
HK1258212A1 (en) 2019-11-08
MX367912B (es) 2019-09-11
EA035998B1 (ru) 2020-09-10
CN112979630A (zh) 2021-06-18
TR201907763T4 (tr) 2019-06-21
CA2965512C (en) 2020-03-10
CN107108599A (zh) 2017-08-29
BR122017023050A2 (pt) 2019-09-10
AR110155A2 (es) 2019-02-27
MX2017005689A (es) 2018-02-19
WO2016069974A1 (en) 2016-05-06
EP3354651B1 (en) 2021-01-06
US10150762B2 (en) 2018-12-11
ME03426B (me) 2020-01-20
EP3212643B1 (en) 2019-03-20
IL255648B (en) 2020-06-30
JP2019059728A (ja) 2019-04-18
CR20170166A (es) 2017-08-22
EA201790942A1 (ru) 2017-09-29
CL2018000436A1 (es) 2018-07-06
SG10201805355YA (en) 2018-07-30
US20170327492A1 (en) 2017-11-16
EA201891562A2 (ru) 2018-12-28
JO3571B1 (ar) 2020-07-05
PH12017500800B1 (en) 2017-10-02
DK3212643T3 (da) 2019-05-13
JOP20200117A1 (ar) 2017-06-16
CL2019001514A1 (es) 2019-10-04
IL251865A0 (en) 2017-06-29
BR112017008816A2 (pt) 2017-12-19
LT3212643T (lt) 2019-06-10
TWI705057B (zh) 2020-09-21
MA40873A (fr) 2017-09-05
ZA201805860B (en) 2019-11-27
AU2015339087A1 (en) 2017-05-11
AR102480A1 (es) 2017-03-01
MX369567B (es) 2019-11-12
PH12017500800A1 (en) 2017-10-02
SG11201703323PA (en) 2017-05-30
KR20170127580A (ko) 2017-11-21
PE20171649A1 (es) 2017-11-13
KR20170078750A (ko) 2017-07-07
JP2018500287A (ja) 2018-01-11
CR20170542A (es) 2018-02-20

Similar Documents

Publication Publication Date Title
PE20180250A1 (es) ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT
EP4073232A4 (en) ORGANOID CULTURES
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
CR20150500A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril- aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
EP3422198A4 (en) CACHEKOHÄRENZBETRIEBSEN FOR MULTICHIP MULTIPROCESSOR AND MULTICHIP MULTIPROCESSOR
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EP3467912A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3467911A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3522271A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL SUBSTANCE, AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3467913A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE MATERIAL
MA42488A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
PT2878579T (pt) Processo para o tratamento de uma purga de carbonato de sódio
TR201820513T4 (tr) Roryt modülatörleri olarak tiazoller.
CL2018000057A1 (es) Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
HUE062863T2 (hu) Eljárás szulfid szilárd elektrolit elõállítására
PE20171619A1 (es) Metodo para prevenir o tratar la perdida de la audicion
PE20190150A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT
HUE053924T2 (hu) Kompozíció cukorbetegség kezelésére
LT3618821T (lt) Nefrogeninio necukrinio diabeto valdymas
EP3894614C0 (en) ELECTROCHEMICAL REACTOR
HUE062935T2 (hu) Eljárás elasztomer bõr elõállítására
EP3750443A4 (en) STRUCTURAL ARRANGEMENT OF TOPS ON SANDALS
EP3398609A4 (en) METHOD FOR PRODUCING A RECOMBINANT HORSE-CHORIONGONADOTROPIN, VETERINARY COMPOSITION AND ITS USE
AR098134A1 (es) Compuestos de urea